MARIA PURIFICACION
MARTINEZ DEL PRADO
IRAKASLE ELKARTUA
![Foto de MARIA PURIFICACION](/img/nophoto.png)
![Foto de Hospital Universitari de Bellvitge](/img/noimage_org.png)
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaHospital Universitari de Bellvitge -ko ikertzaileekin lankidetzan egindako argitalpenak (7)
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
2021
-
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475
-
Incidence and clinical pattern of contralateral synchronous and metachronous germ cell testicular cancer
Urologic Oncology: Seminars and Original Investigations, Vol. 39, Núm. 2, pp. 135.e17-135.e23
-
The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study
Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 11, pp. 2791-2800
2018
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
2013
2010
-
Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE)
Annals of Oncology, Vol. 21, Núm. 9, pp. 1794-1803